Reason for request
Assessment of change of dose permitting use in children aged between 2 and 16.
Clinical Benefit
| Substantial |
The clinical benefit provided by DUROGESIC in children is substantial. |
Clinical Added Value
| Comments without ASMR value |
DUROGESIC has previously been recognised by the Transparency Committee as providing actual benefit in adults, and it provides the same benefit for children over 2. |
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
sA0KRRavUZuALT8A
